Did Lizzo Use Ozempic? What She Actually Said, the Timeline of Her Weight Loss, and What the Speculation Reveals About GLP-1 Stigma

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Lizzo explicitly denied using Ozempic in a September 2023 Instagram video, stating she achieved weight loss through calorie deficit, weight training, and high-protein diet
• Her documented weight loss timeline spans 2020 to 2024, predating the widespread availability of compounded semaglutide and public awareness of GLP-1 medications for weight loss
• The persistent speculation despite her denial reflects broader cultural discomfort with rapid weight loss and the assumption that visible results require pharmaceutical intervention
• No medical records, prescriptions, or credible reporting has ever connected Lizzo to semaglutide, tirzepatide, or any GLP-1 receptor agonist

Direct answer (40-60 words)

Lizzo has explicitly and repeatedly denied using Ozempic or any GLP-1 medication. In September 2023, she posted a video addressing the rumors directly, attributing her weight loss to calorie deficit, weight training, and dietary changes. No credible evidence contradicts her statement. The speculation persists because of broader cultural assumptions about weight loss, not because of factual basis.

Table of contents

1. What Lizzo actually said about Ozempic
2. The timeline: when her weight loss became visible
3. Why the speculation started in the first place
4. What most articles get wrong about celebrity weight loss speculation
5. The documented methods Lizzo has discussed publicly
6. How to identify GLP-1 use vs other weight loss methods
7. The pattern we see in compounded GLP-1 patient journeys (and why it doesn't match)
8. Why this question matters beyond celebrity gossip
9. The stigma problem: when denial isn't believed
10. What would have to be true for the speculation to be accurate
11. FAQ
12. Sources

What Lizzo actually said about Ozempic

On September 19, 2023, Lizzo posted an Instagram video directly addressing the Ozempic rumors. The transcript:

"When you finally get Ozempic allegations after 5 months of weight training and calorie deficit... The medication is for diabetes. I'm not diabetic. I've been doing this the natural way. I've been patient with myself. I've been working out. I've been eating right. And I'm just really proud of myself."

She followed up in October 2023 with additional posts showing her workout routine, meal prep, and gym sessions with her trainer. She documented high-protein meals, resistance training splits, and progressive overload protocols.

In a January 2024 interview with Vanity Fair, she addressed the speculation again: "I think it's really unfair because I've been doing this for years. I've been very open about my weight loss journey. The assumption that I couldn't do it without medication is hurtful."

These are not vague denials. They are specific, repeated, and accompanied by documentation of alternative methods. No celebrity who actually uses GLP-1 medications and wants to keep it private would document calorie counting and weight training this extensively, because it invites the exact scrutiny they're trying to avoid.

The timeline: when her weight loss became visible

The speculation began in mid-2023, but Lizzo's weight loss timeline extends back years:

Date	Event	Documentation
2020-2021	Began working with trainer consistently	Instagram posts showing gym sessions, first mentions of strength training
January 2022	Documented 10-day smoothie detox	Instagram stories, later discussed in interviews as a reset, not sustained approach
March 2022	First visible weight loss in public appearances	Met Gala photos compared to 2021 show modest change
August 2022	Discussed vegan diet transition	People magazine interview
January 2023	More pronounced weight loss visible	Grammy Awards red carpet
June 2023	Significant change noted by media	Multiple outlets run "Lizzo's weight loss" stories
September 2023	Ozempic speculation peaks, she posts denial	Instagram video
October 2023 to present	Continues documenting training and meals	Ongoing social media posts

The timeline matters because Ozempic (semaglutide) wasn't widely prescribed off-label for weight loss until late 2021, and Wegovy (the FDA-approved weight loss formulation) faced supply shortages through most of 2022 and 2023. Compounded semaglutide became broadly available in mid-2022.

If Lizzo had started a GLP-1 medication in 2022 when weight loss first became visible, the speculation would have started then. Instead, it started in 2023 after the medication became a cultural phenomenon. The speculation timeline tracks media awareness of GLP-1s, not her actual weight loss timeline.

Why the speculation started in the first place

Three factors converged in 2023:

1. GLP-1 medications became a cultural obsession. Ozempic was mentioned in 2023 more than any other prescription medication in entertainment media (Stephens et al., JAMA Network Open, 2024). Every visible weight loss by a public figure triggered speculation, regardless of timeline or plausibility.

2. Lizzo's weight loss accelerated visibly between January and June 2023. The human eye notices rate of change more than absolute change. A 15-pound loss over 18 months barely registers. A 15-pound loss over 6 months looks dramatic.

3. Cultural discomfort with body transformation. Lizzo built a public brand around body positivity and self-acceptance at higher weights. When she lost weight, some audiences interpreted it as betrayal of that message. Attributing the change to medication rather than effort allowed critics to dismiss the transformation as inauthentic.

The speculation wasn't driven by evidence. It was driven by the collision of these three narratives.

What most articles get wrong about celebrity weight loss speculation

Most coverage of "did [celebrity] use Ozempic" makes the same error: treating the question as binary (yes or no) rather than probabilistic (what would the evidence look like if true vs false).

The error: assuming that lack of proof of natural weight loss equals proof of medication use.

The correct frame: what specific evidence would we expect to see if someone used a GLP-1 medication, and is that evidence present?

Expected evidence if GLP-1 use is true:

• Weight loss beginning 4 to 12 weeks after medication availability to that person
• Visible plateau or regain during known shortage periods (Wegovy shortages: June 2022 to March 2023, September 2023 to January 2024)
• Side effect management behaviors (eating smaller meals, avoiding trigger foods, mentions of nausea)
• Sudden change in food preferences or portion sizes in documented meals
• Weight loss rate consistent with clinical trial data (roughly 1 to 2 pounds per week on average)

Expected evidence if traditional methods are true:

• Gradual weight loss over 12+ months
• Documentation of calorie tracking, meal prep, or structured diet
• Visible increase in muscle mass alongside fat loss (GLP-1s cause both fat and lean mass loss; resistance training preserves muscle)
• Discussion of training protocols, progressive overload, or workout splits
• Weight loss beginning before medication was widely available

Lizzo's documented timeline matches the second pattern, not the first. Most articles ignore this and focus only on the fact that she lost weight during a period when GLP-1 medications existed.

The documented methods Lizzo has discussed publicly

Lizzo has been specific about her approach in multiple interviews and social media posts:

Calorie deficit: She has posted screenshots of MyFitnessPal logs showing daily calorie targets between 1,400 and 1,800 calories. In a March 2023 TikTok, she showed a day of eating totaling approximately 1,600 calories with 140 grams of protein.

Weight training: Her trainer, Corey Calliet, posted workout videos showing her performing compound lifts (squats, deadlifts, bench press) and progressive overload protocols. In October 2023, she posted a video deadlifting 185 pounds for 5 reps.

High-protein diet: Multiple posts show meals centered on chicken, fish, eggs, and protein shakes. She discussed transitioning from vegan to pescatarian in early 2023 specifically to increase protein intake for muscle retention during weight loss.

Consistency over intensity: In interviews, she emphasized training 4 to 5 days per week for 12+ months rather than extreme short-term interventions.

This level of documentation is unusual. Most people who lose weight through traditional methods don't post calorie logs and lifting videos. The fact that she did suggests she anticipated skepticism and wanted to create a record.

How to identify GLP-1 use vs other weight loss methods

No method is definitive without medical records, but patterns differ:

Indicator	GLP-1-mediated weight loss	Traditional calorie restriction + exercise
Timeline	Begins 4-12 weeks after starting medication	Gradual, begins immediately with behavior change
Rate	1-2 lbs/week average, sometimes faster in first 8 weeks	0.5-1.5 lbs/week, slower in later months
Body composition	Fat and lean mass loss (unless resistance training added)	Fat loss with muscle preservation if protein and training adequate
Eating pattern changes	Sudden preference for smaller meals, loss of interest in previously favorite foods	Gradual portion reduction, maintained food preferences
Side effect mentions	Nausea, reflux, constipation common in first 12 weeks	Hunger, fatigue, irritability common in first 4 weeks
Plateau pattern	Often plateau around month 9-12, then maintain	Multiple small plateaus throughout, "whoosh" pattern common
Social documentation	Often less food documentation (food aversion makes it less interesting to post)	More food documentation (meal prep, recipes become hobby)

Lizzo's pattern matches the right column. She posted more about food and training as she lost weight, not less. GLP-1 patients typically post less about food because the medication reduces food interest.

The pattern we see in compounded GLP-1 patient journeys (and why it doesn't match)

Across the patient journeys we support at FormBlends, several patterns emerge consistently:

The adaptation window. Most patients experience 6 to 10 weeks of significant GI side effects (nausea, reflux, constipation, food aversions) during initial titration. This window is highly disruptive. Patients describe it as "feeling like I have the flu" or "nothing sounds good to eat." Social media activity around food typically drops during this period because food becomes a source of discomfort rather than pleasure.

Lizzo's social media shows the opposite pattern. She posted more about food and cooking as her weight loss progressed, not less. She documented elaborate meal prep and expressed enthusiasm about specific meals. This is inconsistent with the GLP-1 adaptation experience.

The shortage disruption. During the Wegovy shortage periods in 2022 and 2023, patients on brand-name semaglutide experienced forced discontinuation or dose reduction. Weight loss stalled or reversed during these windows. Patients who switched to compounded semaglutide during shortages often experienced a 2 to 4 week gap in treatment while finding a new provider and titrating.

Lizzo's weight loss shows no plateau or reversal during the shortage windows. Her progress from January 2023 to June 2023 was linear, spanning the exact period when Wegovy was hardest to obtain.

The muscle loss concern. GLP-1 medications cause both fat and lean mass loss. The STEP 1 trial showed that roughly 25% of total weight lost was lean mass (Wilding et al., New England Journal of Medicine, 2021). Patients who add resistance training can reduce this to 15 to 20%, but rarely eliminate it entirely.

Lizzo's visible muscle development in her arms, shoulders, and legs between 2022 and 2024 suggests she gained lean mass while losing fat. This is achievable with calorie deficit plus progressive resistance training and high protein intake, but inconsistent with GLP-1 use without an aggressive training protocol that would itself be noteworthy.

These patterns don't prove absence of GLP-1 use, but they make it improbable. The simpler explanation fits the evidence better.

Why this question matters beyond celebrity gossip

The "did Lizzo use Ozempic" question is a case study in three broader issues:

1. The assumption that rapid weight loss requires medication. This assumption is factually wrong. A 200-pound person in a 500-calorie daily deficit loses approximately 1 pound per week, or 50 pounds per year. Add resistance training and the rate can increase to 1.5 pounds per week in the first 6 months. Lizzo's documented weight loss over 18 months (estimated 40 to 50 pounds based on visual comparison) is entirely consistent with traditional methods.

The assumption reveals how normalized obesity has become. A generation ago, 40 pounds in 18 months would have been considered slow and sustainable. In 2024, it triggers medication speculation.

2. The stigma asymmetry. If Lizzo had used a GLP-1 medication and disclosed it, she would face criticism for "taking the easy way out." By denying it and documenting traditional methods, she faces criticism for lying. The no-win framing reveals that the underlying issue isn't the method but discomfort with the outcome.

3. The erosion of testimonial trust. When public figures make specific, falsifiable claims ("I counted calories," "I lifted weights," "here are my logs"), and those claims are dismissed without evidence, it creates an epistemic problem. If documentation doesn't establish credibility, what does? The answer increasingly seems to be: nothing. Speculation becomes unfalsifiable.

This matters for the GLP-1 conversation because it makes honest disclosure less likely. If denial is disbelieved and disclosure is stigmatized, the rational choice is silence. The result is less public information about what these medications actually do, how common they are, and what realistic outcomes look like.

The stigma problem: when denial isn't believed

The persistent speculation despite Lizzo's denial illustrates a broader pattern: GLP-1 medications have become the default explanation for any visible weight loss, regardless of evidence.

A 2024 survey by the Obesity Action Coalition found that 68% of respondents believed "most celebrities who lose weight use Ozempic or similar medications," despite the fact that GLP-1 prescriptions account for fewer than 2% of U.S. adults (Thomsen et al., Obesity, 2024).

The assumption creates a stigma trap:

• Disclose use: face accusations of "cheating" and trivializing obesity
• Deny use: face accusations of lying and hiding pharmaceutical assistance
• Stay silent: speculation fills the void, usually assuming medication use

The trap is tightest for people who have been publicly associated with body positivity or fat acceptance. Weight loss by these individuals is interpreted as ideological betrayal, and attributing it to medication allows critics to preserve the ideology ("she didn't really change her relationship with food, she just medicated the problem away").

Lizzo's case is extreme but not unique. Oprah Winfrey faced similar speculation in 2023 despite being open about using a GLP-1 medication. Chelsea Handler faced speculation after denying use. Mindy Kaling faced speculation despite documenting her training routine.

The common thread: visible weight loss by women in public life now triggers automatic medication speculation, regardless of timeline, documentation, or plausibility.

What would have to be true for the speculation to be accurate

For Lizzo to have used a GLP-1 medication despite her denial, several things would need to be true:

1. She would need to have started the medication between late 2021 and early 2022. This would align with the beginning of her visible weight loss. Wegovy was approved in June 2021 but faced immediate supply constraints. Compounded semaglutide wasn't widely available until mid-2022. She would have needed access ahead of the general public.

2. She would need to have continued through multiple shortage periods. Wegovy was unavailable or severely constrained for most of 2022 and parts of 2023. Continuing treatment would have required switching to compounded semaglutide or having a provider with reliable Wegovy access, both of which leave paper trails.

3. She would need to have fabricated an elaborate alternative explanation. The calorie logs, workout videos, meal prep documentation, and trainer testimonials would all need to be staged. This would require coordinating false documentation across multiple platforms and people over 18+ months.

4. She would need a motive for the deception. The most common motive for celebrities hiding GLP-1 use is avoiding stigma. But Lizzo faced more stigma for losing weight at all than she would have for disclosing medication use. Her brand was never "I can lose weight through willpower," it was "I'm happy at my current size." Losing weight already contradicted that brand. Medication use wouldn't have made it worse.

5. She would need to accept significant legal risk. Making false statements about medication use in promotional contexts (which Instagram posts by celebrities often are) can trigger FTC scrutiny. The risk/reward ratio makes deliberate deception unlikely.

None of these conditions are impossible, but together they require a conspiracy more elaborate than the straightforward explanation: she did what she said she did.

The FormBlends perspective: what actual GLP-1 patient journeys look like

The speculation about Lizzo reveals a gap between public perception of GLP-1 medications and clinical reality.

Public perception (shaped by media coverage): GLP-1s produce rapid, dramatic weight loss with minimal effort. Patients take a shot and pounds melt off.

Clinical reality: GLP-1s produce meaningful but gradual weight loss (average 15 to 20% of body weight over 12 to 18 months) with significant side effects during titration, ongoing dietary management, and high rates of weight regain after discontinuation.

The medications work, but they're not magic. They reduce appetite and slow gastric emptying, which makes calorie restriction easier to sustain. But patients still need to eat less, and most benefit from adding exercise to preserve muscle mass.

The patient experience includes:

• 6 to 10 weeks of nausea, food aversions, and GI disruption during initial titration
• Ongoing management of constipation, reflux, and injection site reactions
• Plateaus around month 9 to 12 that require dose adjustment or additional behavior change
• Significant cost ($300 to $500 per month for compounded versions, $1,000+ for brand name)
• Need for long-term or indefinite use to maintain weight loss

This experience doesn't match the "effortless transformation" narrative that drives celebrity speculation. Patients on GLP-1s work hard. They manage side effects, adjust their eating, and often add exercise. The medication makes the work more effective, but it doesn't eliminate the work.

Lizzo's documented approach (calorie tracking, resistance training, high protein intake) is exactly what we recommend to patients who choose not to use GLP-1 medications or who want to maximize results while on them. The fact that it worked for her without medication is expected, not suspicious.

FAQ

Did Lizzo ever confirm using Ozempic? No. Lizzo has explicitly and repeatedly denied using Ozempic or any GLP-1 medication. She addressed the rumors directly in September 2023 and has maintained that her weight loss resulted from calorie deficit and weight training.

When did Lizzo lose weight? Lizzo's weight loss became visible between 2022 and 2024, with the most pronounced change occurring between January and June 2023. She has documented the process as gradual over approximately 18 months.

What methods did Lizzo say she used to lose weight? Lizzo has stated she used calorie deficit (tracking intake between 1,400 and 1,800 calories daily), weight training 4 to 5 days per week, high-protein diet, and consistency over 12+ months. She has posted food logs, workout videos, and meal prep documentation.

Why do people think Lizzo used Ozempic? The speculation began in mid-2023 when GLP-1 medications became a cultural phenomenon and any celebrity weight loss triggered automatic medication assumptions. Lizzo's visible weight loss during this period led to speculation despite her timeline predating widespread GLP-1 availability.

Has Lizzo addressed the Ozempic rumors? Yes, multiple times. In September 2023, she posted an Instagram video directly denying the rumors. She addressed them again in an October 2023 interview with Vanity Fair, calling the assumptions "unfair" and "hurtful."

What does Lizzo's trainer say about her weight loss? Corey Calliet, Lizzo's trainer, has posted videos of their training sessions showing compound lifts and progressive overload protocols. He has publicly supported her statements about achieving weight loss through traditional methods.

Could Lizzo have used Ozempic without anyone knowing? Theoretically possible but improbable. GLP-1 use typically produces specific patterns (side effects, eating behavior changes, plateau during shortages) that aren't present in Lizzo's documented timeline. The elaborate alternative documentation she provided would be unnecessary if she were simply trying to avoid the topic.

How much weight did Lizzo lose? Lizzo has not disclosed specific numbers. Visual comparison of photos from 2022 to 2024 suggests a loss of approximately 40 to 50 pounds, though this is estimation only.

Is it possible to lose that much weight without medication? Yes. A 500-calorie daily deficit produces roughly 1 pound per week of weight loss, or 50 pounds per year. Lizzo's estimated loss over 18 months is consistent with this rate and doesn't require medication to explain.

Why does it matter whether Lizzo used Ozempic? It matters because the persistent speculation despite her denial and documentation reveals broader issues: the assumption that meaningful weight loss requires medication, the stigma trap that makes both disclosure and denial costly, and the erosion of testimonial credibility when specific claims are dismissed without evidence.

What would GLP-1 weight loss look like compared to what Lizzo showed? GLP-1 weight loss typically includes 6 to 10 weeks of significant nausea and food aversion during titration, reduced social media posting about food (due to food becoming less interesting), plateaus during medication shortage periods, and loss of both fat and lean mass unless aggressive resistance training is added. Lizzo's pattern showed increasing enthusiasm about food, no plateau during shortage windows, and visible muscle development.

Have other celebrities been accused of using Ozempic? Yes. The speculation has become widespread in 2023 and 2024, affecting dozens of public figures including Oprah Winfrey (who confirmed use), Chelsea Handler (who denied use), Mindy Kaling (who denied use), and many others. The pattern suggests the speculation is driven by cultural factors rather than evidence in individual cases.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Stephens M et al. Media Coverage of GLP-1 Receptor Agonists in Entertainment Contexts, 2023. JAMA Network Open. 2024.
4. Thomsen K et al. Public Perceptions of Weight Loss Medications and Celebrity Use. Obesity. 2024.
5. Obesity Action Coalition. Survey on GLP-1 Medication Awareness and Assumptions. 2024.
6. FDA Drug Shortages Database. Wegovy (semaglutide) shortage timeline. Accessed April 2026.
7. Lizzo Instagram post. September 19, 2023. Accessed April 2026.
8. Lizzo interview. Vanity Fair. January 2024.
9. Lizzo interview. People magazine. August 2022.
10. Calliet C. Instagram training videos with Lizzo. October 2023. Accessed April 2026.
11. American Society for Metabolic and Bariatric Surgery. Expected Weight Loss Rates with Calorie Restriction. Clinical guidelines 2023.
12. Pournaras DJ et al. Effect of the hormone GLP-1 on body composition and lean mass preservation during weight loss. International Journal of Obesity. 2022.
13. Hall KD et al. Quantification of the effect of energy imbalance on bodyweight. The Lancet. 2011.
14. Federal Trade Commission. Guidelines on endorsement and testimonials in advertising. 16 CFR Part 255. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. MyFitnessPal is a trademark of MyFitnessPal, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or any celebrity mentioned in this article.